Search hospitals > Massachusetts > Brighton

St. Elizabeth's Medical Center

Claim this profile
Brighton, Massachusetts 02135
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Cancer
Conducts research for Heart Failure
145 reported clinical trials
7 medical researchers
Photo of St. Elizabeth's Medical Center in BrightonPhoto of St. Elizabeth's Medical Center in Brighton

Summary

St. Elizabeth's Medical Center is a medical facility located in Brighton, Massachusetts. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Heart Failure and other specialties. St. Elizabeth's Medical Center is involved with conducting 145 clinical trials across 176 conditions. There are 7 research doctors associated with this hospital, such as Jacob Sands, MD, Olga Kozyreva, MD, Alys Malcolm, and Lawrence Garcia.

Area of expertise

1Lung Cancer
Global Leader
St. Elizabeth's Medical Center has run 20 trials for Lung Cancer. Some of their research focus areas include:
Stage II
Stage I
Stage III
2Breast Cancer
Global Leader
St. Elizabeth's Medical Center has run 18 trials for Breast Cancer. Some of their research focus areas include:
ER positive
HER2 negative
PR positive

Top PIs

Clinical Trials running at St. Elizabeth's Medical Center

Non-Small Cell Lung Cancer
Lung Cancer
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer
Esophageal Cancer
Esophageal Adenocarcinoma
Cancer
ALK Gene Rearrangement
Squamous Cell Carcinoma
Parkinson's Disease
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Image of trial facility.

Genetic Testing

for Early-Stage Lung Cancer

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Recruiting0 awards N/A4 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at St. Elizabeth's Medical Center?
St. Elizabeth's Medical Center is a medical facility located in Brighton, Massachusetts. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Heart Failure and other specialties. St. Elizabeth's Medical Center is involved with conducting 145 clinical trials across 176 conditions. There are 7 research doctors associated with this hospital, such as Jacob Sands, MD, Olga Kozyreva, MD, Alys Malcolm, and Lawrence Garcia.